Cell therapy for advanced multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial is testing a new cell therapy (called Eque-cel) for people with multiple myeloma that has come back or stopped responding to standard treatments. The therapy uses your own immune cells to attack the myeloma cells. You may qualify if you've tried at least three prior treatment combinations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Are between 18 and 70 years old
- Have multiple myeloma that has returned or not responded to at least three prior treatment lines, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody
- Have measurable disease (detectable M-protein in blood or urine, or elevated free light chains)
- Have adequate organ function, including blood counts, liver, kidney, heart, and lung function
- Have not had certain prior treatments (like BCMA-targeted therapy, a recent stem cell transplant, or certain medications within a few weeks before apheresis) and no active infections or other serious conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a type of cancer treatment called CAR-T cell therapy for people with multiple myeloma that has relapsed (come back) or is refractory (did not respond to treatment). The treatment uses your own immune cells to attack the cancer. This study is real-world, meaning it happens in everyday clinical practice, not in a strict research setting.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
This trial tests a new treatment where your own immune cells (T cells) are collected, modified to find and attack myeloma cells, and given back to you. It is for people with multiple myeloma that has come back or not responded to several standard treatments.
This study tests a new CAR-T cell therapy called Eque-cel for people with multiple myeloma that no longer responds to lenalidomide. It aims to see if this treatment can help control the disease after 1-2 prior therapies.
This trial tests a one-time BCMA CAR-T cell treatment for people with multiple myeloma that relapsed or did not respond well to prior treatments. It may help by training your own immune cells to recognize and attack myeloma cells.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.